Lung Disease Therapeutics Market
Lung disease diagnoses have increased as a result of increased awareness of new medical diagnostic equipment and improved treatments
Lung Disease Therapeutics Market by Disease Type, Treatment Type, Distribution Channel & Region - Forecast 2022 - 2032
Lung Disease Therapeutics Market Snapshot (2022-2032)
[280 Pages Report] The global lung disease therapeutics market garnered a market value of US$ 79,833.6 Million in 2022 and is expected to accumulate a market value of US$ 145,960.2 Million by registering a CAGR of 6.21% in the forecast period 2022-2032.
Growth of the lung disease therapeutics market can be attributed to increasing air pollution and the rising prevalence of COPD. The market for lung disease therapeutics registered a CAGR of 5.2% in the historical period 2016-2021.
|
Data Points |
Key Statistics |
|
Estimated Base Year Value (2021) |
US$ 75,234.14 Million |
|
Expected Market Value (2022) |
US$ 79,833.6 Million |
|
Anticipated Forecast Value (2032) |
US$ 145,960.2 Million |
|
Projected Growth Rate (2022-2032) |
6.21% CAGR |
Lungs are the complex human organ that brings in oxygen and expels carbon dioxide by expanding and relaxing continuously. Lung disease is one of the most common medical conditions globally. Lung disease is very severe and is highly responsible for increasing mortality around the globe. Lung disease lead to uneasiness and complications in respiration.
Some major lung diseases are COPD, asthma, bronchopulmonary dysplasia, and pulmonary fibrosis. Basically, there are two types of treatment for lung disease viz drug treatment and oxygen therapy. Drug treatment is most preferred by physicians as well as patients owing to its instant effect. Oxygen therapy is provided to COPD patients through ventilators and concentrators for long-term care.
Let us know your requirement to get
100% FREE customization
Which Are Some Prominent Drivers Spearheading Lung Disease Therapeutics Market Growth?
Increasing Prevalence of Lung Diseases Drives the Growth of the Market
The rising prevalence of COPD and asthma are the primary factors driving the growth of lung disease therapeutics market. The change in lifestyle of people and increase in numbers of smokers globally will propel the growth of lung disease therapeutics market. Besides, rising geriatric population suffering from various lung disease will upsurge the growth of lung disease therapeutics market.
Furthermore, advancement in technology and increasing research and development leads to availability of more efficient drug therapeutics will boost the growth of lung disease therapeutics market.
The lung disease therapeutics market is expected to show exponential growth over the forecast period. The lung disease therapeutics market is classified on the basis of disease type, treatment type and distribution channel. By disease type, COPD segment is expected to dominate the market value of lung disease therapeutics market.
Drug treatment is expected to be the most lucrative segment for lung disease therapeutics market by treatment type. Among all distribution channels, retail pharmacies are expected to show faster growth than other segments.
What Are The Challenges Faced By The Lung Disease Therapeutics Industry?
The Cost Associated with the Treatment of Lung Diseases May Impede the Growth of the Market
Although the lung disease therapeutics market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The high cost of drugs for the treatment of lung disease will restrain the growth of this market to some extent.
Some side effects after consumption of anti-inflammatory drugs will also hinder the growth of the lung disease therapeutics market. All these factors are expected to derail the progress of the lung disease therapeutics market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhy Is North America Emerging As An Opportunistic Lung Disease Therapeutics Market?
Growing Prevalence of Lung Related Disorders to Boost the Growth of the Market
North America is expected to have the maximum market share of the lung disease therapeutics market due to the high number of people suffering from COPD and asthma in the U.S. After North America. In addition, technologically advanced healthcare facilities are contributing to the growth of the market.
Moreover, increasing awareness regarding early therapeutics for lung disease is contributing to the growth of the market. Thus, North America is expected to possess 35.0% market share in 2022.
In addition, with the advent of new treatment therapies such as targeted drug therapy, stereotactic are aiding the growth of lung disease therapeutics market. According to the American Lung Association, COPD is the third most common cause of death in the country.
How Is Europe Likely To Contribute To Lung Disease Therapeutics Market Growth?
Technological Advancement in Healthcare to Drive the Growth of the Market in the Region.
Rising healthcare infrastructure and favorable medical insurance are responsible for the high growth of the lung disease therapeutics market in Western Europe. Rising pollution and climate change in the European region will lead to the robust growth of the lung disease therapeutics market.
Moreover, government initiatives to spread awareness regarding regular lung check-ups is escalating the demand for lung disease therapeutics. Thus, Europe is expected to hold a 29.0% market share in 2022. The region's market is being driven by an increase in the prevalence of chronic disease and Asthma being the most common issue among children.
A number of technological advancements in respiratory diagnostic testing have paved the way for the market's expansion, including the use of artificial intelligence and the internet of things (IoT), among other things.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Will The Asia Pacific Emerge As An Attractive Lung Disease Therapeutics Market?
The High Prevalence of Lung Diseases among the Older Population Led to Increased Demand for Lung Diseases Therapeutics in Asia Pacific
The Asia Pacific is expected to remain at the forefront by generating the largest lung diseases therapeutics market share in the upcoming years. The presence of numerous leading companies in the region is anticipated to drive the regional market. The rising aging population prone to lung diseases across developing countries, such as India and China is likely to propel the demand for lung disease therapeutics in the Asia Pacific.
The high penetration rate of state-of-the-art devices and the presence of a well-established healthcare system across Asia Pacific are a couple of other factors that would foster the market. For instance, In August 2022- Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers.
Innovent is a leading biopharmaceutical company with strong clinical development capabilities and a broad commercial footprint in China.
Start-Ups For Lung Disease Therapeutics Market
Key start-up players in the lung disease therapeutics are Omnispirant, Atriva Therapeutics, Altavant Sciences, Exvastat and ReAlta Life Sciences.
- Altavant Sciences, a key start-up in the lung disease therapeutics market is developing small molecule inhibitors as respiratory drugs for the treatment of COPD.
Market Competition
Examples of some of the market participants in lung disease therapeutics market identified across the value chain include GlasxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi, Roche, Teva Pharmaceuticals, Astellas Pharma, Asmacure Ltée, Dr. Reddy’s Laboratories Ltd.
Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as GlasxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Sanofi account for considerable market size, several regional level players are also operating across key growth regions, particularly in the Asia Pacific.
- In June 2022, AstraZeneca announced that the company’s Imfinzi exhibited positive high-level results in resectable non-small cell lung cancer.
- In February 2020 – Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorization for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults. In September, the U.S. Food and Drug Administration (FDA) approved nintedanib as the first and only medicine to slow the rate of decline in pulmonary function in adults living with SSc-ILD. Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in other countries including Canada, Japan, and Brazil.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 6.21% from 2022 to 2032 |
|
Expected Market Value (2022) |
US$ 79,833.6 Million |
|
Anticipated Forecast Value (2032) |
US$ 145,960.2 Million |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled In The Lung Disease Therapeutics Industry Survey
Lung Disease Therapeutics Market by Disease Type:
- Lung Disease Therapeutics for COPD
- Lung Disease Therapeutics for Chronic Bronchitis
- Lung Disease Therapeutics for Emphysema
- Lung Disease Therapeutics for Bronchopulmonary dysplasia
- Lung Disease Therapeutics for Pulmonary Fibrosis
- Lung Disease Therapeutics for Asthma
- Lung Disease Therapeutics for Other Lung Disease Therapeutics
Lung Disease Therapeutics Market by Treatment Type:
- Lung Disease Therapeutic through Drugs
- Diuretics
- Steroids
- Lung Disease Therapeutics through Bronchodilators
- Lung Disease Therapeutics through Antibiotics
- Lung Disease Therapeutics through Anti-inflammatory Agents
- Lung Disease Therapeutics through Oxygen Therapy
- Lung Disease Therapeutics through Other Treatment Types
Lung Disease Therapeutics Market by Distribution Channel:
- Lung Disease Therapeutics across Hospital Pharmacies
- Lung Disease Therapeutics across Retail Pharmacies
- Lung Disease Therapeutics across Online Pharmacies and E-commerce
- Lung Disease Therapeutics across Drugstores
- Lung Disease Therapeutics across Other Distribution Channels
Lung Disease Therapeutics Market by Region:
- North America Lung Disease Therapeutics Market
- Latin America Lung Disease Therapeutics Market
- Europe Lung Disease Therapeutics Market
- Asia Pacific Lung Disease Therapeutics Market
- Middle East & Africa Lung Disease Therapeutics Market
Frequently Asked Questions
FMI projects the global lung disease therapeutics market to expand at a 5.6% value CAGR by 2032
North America is expected to be the most opportunistic with a 35.0% share of the total lung disease therapeutics market
GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Sanofi, are some prominent lung disease therapeutics market manufacturers.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2022-2032
5.3.1. COPD
5.3.2. Chronic Bronchitis
5.3.3. Emphysema
5.3.4. Bronchopulmonary Dysplasia
5.3.5. Pulmonary Fibrosis
5.3.6. Asthma
5.3.7. Others
5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Disease Type, 2022-2032
6. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Treatment Type, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment Type, 2022-2032
6.3.1. Drugs
6.3.1.1. Diuretics
6.3.1.2. Bronchodilators
6.3.1.3. Steroids
6.3.2. Antibiotics
6.3.3. Anti-inflammatory Agents
6.3.4. Oxygen Therapy
6.3.5. Others
6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2017-2021
6.5. Absolute $ Opportunity Analysis By Treatment Type, 2022-2032
7. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies & E-commerce
7.3.4. Drugstores
7.3.5. Others
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
8. Global Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. US
9.2.1.2. Canada
9.2.2. By Disease Type
9.2.3. By Treatment Type
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By Treatment Type
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Disease Type
10.2.3. By Treatment Type
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By Treatment Type
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. U.K.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Disease Type
11.2.3. By Treatment Type
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Type
11.3.3. By Treatment Type
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Rest of Asia Pacific
12.2.2. By Disease Type
12.2.3. By Treatment Type
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Type
12.3.3. By Treatment Type
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. MEA Lung Disease Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Disease Type
13.2.3. By Treatment Type
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Disease Type
13.3.3. By Treatment Type
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Lung Disease Therapeutics Market Analysis
14.1. US
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Disease Type
14.1.2.2. By Treatment Type
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Disease Type
14.2.2.2. By Treatment Type
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Disease Type
14.3.2.2. By Treatment Type
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Disease Type
14.4.2.2. By Treatment Type
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Disease Type
14.5.2.2. By Treatment Type
14.5.2.3. By Distribution Channel
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Disease Type
14.6.2.2. By Treatment Type
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Disease Type
14.7.2.2. By Treatment Type
14.7.2.3. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Disease Type
14.8.2.2. By Treatment Type
14.8.2.3. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Disease Type
14.9.2.2. By Treatment Type
14.9.2.3. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Disease Type
14.10.2.2. By Treatment Type
14.10.2.3. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Disease Type
14.11.2.2. By Treatment Type
14.11.2.3. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Disease Type
14.12.2.2. By Treatment Type
14.12.2.3. By Distribution Channel
14.13. GCC Countries
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Disease Type
14.13.2.2. By Treatment Type
14.13.2.3. By Distribution Channel
14.14. South Africa
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Disease Type
14.14.2.2. By Treatment Type
14.14.2.3. By Distribution Channel
14.15. Israel
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Disease Type
14.15.2.2. By Treatment Type
14.15.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Disease Type
15.3.3. By Treatment Type
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. GlasxoSmithKline
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Boehringer Ingelheim
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. AstraZeneca
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Novartis
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Sanofi
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Roche
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Teva Pharmaceuticals
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Astellas Pharma
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Odan Laboratories
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Dr. Reddy’s Laboratories Ltd
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.11. Eli Lilly and Company
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.12. Pfizer Inc.
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 3: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032
Table 4: Global Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 5: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 6: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 7: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032
Table 8: North America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 9: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 10: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 11: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032
Table 12: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 13: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 15: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032
Table 16: Europe Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 17: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 18: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 19: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032
Table 20: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 21: MEA Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: MEA Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Disease Type, 2017-2032
Table 23: MEA Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Treatment Type, 2017-2032
Table 24: MEA Lung Disease Therapeutics Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 2: Global Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032
Figure 3: Global Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 4: Global Lung Disease Therapeutics Market Value (US$ Mn) by Region, 2022-2032
Figure 5: Global Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 6: Global Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 9: Global Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 10: Global Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 11: Global Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032
Figure 12: Global Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032
Figure 13: Global Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032
Figure 14: Global Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 15: Global Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 16: Global Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 17: Global Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032
Figure 18: Global Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032
Figure 19: Global Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 20: Global Lung Disease Therapeutics Market Attractiveness by Region, 2022-2032
Figure 21: North America Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 22: North America Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032
Figure 23: North America Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 24: North America Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 26: North America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 29: North America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 30: North America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 31: North America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032
Figure 32: North America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032
Figure 33: North America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032
Figure 34: North America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 35: North America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 36: North America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 37: North America Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032
Figure 38: North America Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032
Figure 39: North America Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 40: North America Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 42: Latin America Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032
Figure 43: Latin America Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 44: Latin America Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 46: Latin America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 49: Latin America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 50: Latin America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 51: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032
Figure 52: Latin America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032
Figure 53: Latin America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032
Figure 54: Latin America Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 55: Latin America Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 56: Latin America Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 57: Latin America Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032
Figure 58: Latin America Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032
Figure 59: Latin America Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 60: Latin America Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032
Figure 61: Europe Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 62: Europe Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032
Figure 63: Europe Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 64: Europe Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 66: Europe Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 69: Europe Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 70: Europe Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 71: Europe Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032
Figure 72: Europe Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032
Figure 73: Europe Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032
Figure 74: Europe Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 75: Europe Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 76: Europe Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 77: Europe Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032
Figure 78: Europe Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032
Figure 79: Europe Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 80: Europe Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032
Figure 81: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 82: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032
Figure 83: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 84: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 85: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 86: Asia Pacific Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: Asia Pacific Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 89: Asia Pacific Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 90: Asia Pacific Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 91: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032
Figure 92: Asia Pacific Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032
Figure 93: Asia Pacific Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032
Figure 94: Asia Pacific Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 95: Asia Pacific Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 96: Asia Pacific Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 97: Asia Pacific Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032
Figure 98: Asia Pacific Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032
Figure 99: Asia Pacific Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 100: Asia Pacific Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032
Figure 101: MEA Lung Disease Therapeutics Market Value (US$ Mn) by Disease Type, 2022-2032
Figure 102: MEA Lung Disease Therapeutics Market Value (US$ Mn) by Treatment Type, 2022-2032
Figure 103: MEA Lung Disease Therapeutics Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 104: MEA Lung Disease Therapeutics Market Value (US$ Mn) by Country, 2022-2032
Figure 105: MEA Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 106: MEA Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: MEA Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: MEA Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Disease Type, 2017-2032
Figure 109: MEA Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Disease Type, 2022-2032
Figure 110: MEA Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Disease Type, 2022-2032
Figure 111: MEA Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Treatment Type, 2017-2032
Figure 112: MEA Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Treatment Type, 2022-2032
Figure 113: MEA Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Treatment Type, 2022-2032
Figure 114: MEA Lung Disease Therapeutics Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 115: MEA Lung Disease Therapeutics Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 116: MEA Lung Disease Therapeutics Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 117: MEA Lung Disease Therapeutics Market Attractiveness by Disease Type, 2022-2032
Figure 118: MEA Lung Disease Therapeutics Market Attractiveness by Treatment Type, 2022-2032
Figure 119: MEA Lung Disease Therapeutics Market Attractiveness by Distribution Channel, 2022-2032
Figure 120: MEA Lung Disease Therapeutics Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
